Anti-smoking pill may be real deal

Helen Palmer Aug 15, 2006
HTML EMBED:
COPY

Anti-smoking pill may be real deal

Helen Palmer Aug 15, 2006
HTML EMBED:
COPY

TEXT OF STORY

SCOTT JAGOW: There’s a new drug for smokers trying to quit. It’s called Chantix. A study out today says it’s the real deal. Now — wink, wink — the maker of the drug paid for the study. But that doesn’t mean it doesn’t work. Helen Palmer reports from the Health Desk at WGBH.


HELEN PALMER: The Journal of the American Medical Association study notes prominently that drug company Pfizer paid for and helped design the clinical trials for Chantix.

But report author Mitchell Nides says independent researchers and the FDA approved the methodology, which tested both the drug and a placebo.

MITCHELL NIDES: All the patients and we were all blinded to which medication people are on. Plus we independently verify all the results before we publish the data.

According to the study, Chantix helped 14% of subjects kick the smoking habit long-term. That’s nearly three times the rate of those who got the placebo.

Pfizer’s selling Chantix for about $3.20 a pill. Smokers spend at least $300 million a year on aids to help them quit.

In Boston, I’m Helen Palmer for Marketplace.

We’re here to help you navigate this changed world and economy.

Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.

In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.

Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.